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Abstract 1 
Histamine and tumor necrosis factor-α (TNF-α) are critical mediators of acute and chronic 2 
inflammation that are generated by mast cells and macrophages in atherosclerotic lesions or 3 
systemically during allergic attacks. Both of them induce activation of vascular endothelium and 4 
thus may play a role in thrombosis. Here we studied the interplay between histamine and TNF-α 5 
in glycoprotein (GP) Ibα-mediated platelet adhesion to cultured human vascular endothelial cells 6 
under static and shear flow conditions. The stimulation of endothelial cells with histamine or 7 
TNF-α increased the number of adherent or slow rolling GP Ibα-coated microbeads or washed 8 
human platelets. However, the application of histamine to endothelium pre-activated by TNF-α 9 
inhibited GP Ibα-mediated platelet adhesion. These effects were found to be associated with 10 
changes in the concentration of ultra large von Willebrand factor (ULVWF) strings anchored to 11 
endothelium. The results of this study indicate that histamine released during mast cell 12 
degranulation may cause or inhibit thrombosis, depending on whether it acts on resting 13 
endothelial cells or on cells pre-activated by other inflammatory stimuli.  14 
 15 
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The adhesion and accumulation of platelets at sites of vascular wall damage or inflammation is 1 
the primary event in both arterial and vein thrombosis [1-5]. It is well established [6-8] that 2 
initial adhesive interactions between platelets and vascular endothelial cells are mediated via 3 
binding of the platelet membrane glycoprotein (GP) Ib-IX-V complex to endothelial von 4 
Willebrand Factor (vWF). Endothelial cells store vWF in its highly-reactive, ultra large form 5 
(ULVWF) within Weibel-Palade bodies [9-11] from which it is secreted constitutively or in 6 
response to thrombogenic stimuli [12-14]. A portion of secreted ULVWF strings are anchored to 7 
the endothelial cell membrane [15, 16]. Platelets adhere to these strings because of high-affinity 8 
binding between the vWF A1 domain and the GP Ibα subunit of the GP Ib-IX-V complex [17, 9 
18]. This process is, however, tightly regulated by hemostatic mediators such as the plasma 10 
protease ADAMTS-13, which promptly cleaves ULVWF into smaller, less reactive dimers, thus 11 
preventing the formation of occlusive thrombi [19-21]. 12 
 Tumor necrosis factor-α (TNF-α) and histamine are important mediators of chronic and 13 
acute inflammation. TNF-α produced by tissue resident macrophages activate endothelial cells 14 
[22] and thus increases the flux of leukocytes to the inflamed tissue [23]. Histamine causes 15 
inflammation when it is released from mast cells and basophils in response to allergen  [24-26]. 16 
It can also be secreted by activated platelets [27, 28]. Bernardo et al. [14] demonstrated that 17 
TNF-α stimulates ULVWF secretion and platelet aggregation to ULVWF strings. Numerous 18 
evidence indicates that histamine can induce the secretion of proteins from Weibel-Palade 19 
bodies, including P-selectin and ULVWF [2, 29-32]. Interestingly, ULVWF generated through 20 
endothelium activation by histamine alone remains associated with the endothelial cell 21 
membrane, likely due to the involvement of P-selectin in the ULVWF anchorage [16]. This leads 22 
to rapid accumulation of platelets at histamine-activated endothelium [16, 27, 33].  23 
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Both TNF-α and histamine can simultaneously reach a high concentration in specific 1 
regions of the body. For instance, the histamine level is high during allergic attacks [24], and 2 
patients with allergy may have chronic inflammatory conditions such as atherosclerosis at which 3 
TNF-α is extensively released [34]. Histamine secretion from mast cells abundantly found in the 4 
atherosclerotic plaques [35] contributes to atherosclerosis even in the absence of the allergic 5 
response [36, 37]. Meanwhile, platelets play a crucial role in this pathological process by either 6 
recruiting leukocytes [38, 39] or by causing acute thrombotic events after rupture of a vulnerable 7 
plaque [40]. The interplay between TNF-α and histamine in platelet-endothelium adhesion and 8 
thrombus formation is not yet studied.  Here, we investigate adhesive interactions of GP Ibα-9 
coated microbeads and human platelets with cultured human endothelial cells exposed to both 10 
TNF-α and histamine under static and shear flow conditions.  11 
12 
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Materials and Methods  1 
Reagents  2 
Histamine, TNF-α, bovine serum albumin (BSA), 2-(N-morpholino)ethanesulfonic 3 
(MES) acid hydrate, and 2% gelatin were obtained from Sigma-Aldrich (St. Louis, MO). Human 4 
recombinant glycoprotein Ibα (GP Ibα) was purchased from R&D systems (Minneapolis, MN). 5 
2.0 µm diameter carboxylate-modified fluorescent latex microspheres (505/515 nm, 6 
FluoSpheres®) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) were purchased 7 
from Invitrogen (Carlsbad, CA). GTI-V3P monoclonal mouse anti-human-vWF (GTI 8 
Diagnostics, Waukesha, WI) was used to block the A1 domain of vWF.  9 
Endothelial culture  10 
Primary human umbilical vein endothelial cells (HUVEC) were purchased from 11 
Invitrogen.  Endothelial cells were grown out in T-75 flasks in low serum growth medium 12 
(M200-LSGS; Invitrogen) supplemented with antibiotics. When 80% or greater confluence was 13 
reached, the cells were harvested by treatment with 0.1% trypsin in EDTA (Sigma-Aldrich), 14 
yielding approximately 2.0×106 cells per flask. HUVEC were reseeded, at passage 4-6, in 0.1% 15 
gelatin-coated 24-well plates for static adhesion assays. Experiments were conducted within 24 16 
hours after HUVEC reached more than 90% confluence in the 24-well plates. All the cells were 17 
maintained at 37°C in a 5% CO2 humidified incubator. 18 
Preparation of GP Ibα-coated microbeads  19 
Covalent coupling of the amino-terminal end of GP Ibα to the carboxylate group on the 20 
surface of latex microspheres (microbeads) was accomplished through carbodiimide chemistry, 21 
catalyzed by EDAC [41], using the protocol by Liu et al. [42]. Briefly, 400 µL of MES buffer 22 
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was added to a 100 µL aliquot of microbeads and mixed by aspiration and sonication for five 1 
minutes. The resulting suspension was then centrifuged at 6,708×g for 10 minutes. Following 2 
centrifugation, the microbead pellet was isolated and re-suspended in 500 µL of MES buffer. 3 
This wash procedure was repeated three times, with the microbead pellet re-suspended in 100 µL 4 
of MES in the final stage. 20 µL of EDAC was then added and mixed by aspiration, followed by 5 
sonication. After a 20 minute incubation period with EDAC at room temperature, 2.5 µL of 6 
recombinant human GP Ibα (50 µg/mL), calculated to yield the surface density of 300 sites/µm2, 7 
was added to the microbead-EDAC suspension. The final suspension was incubated at room 8 
temperature for at least 12 hours before an adhesion assay, with continuous gentle vortexing.  9 
Following the covalent attachment of GP Ibα to the microbead surface, the microbeads 10 
were re-suspended in 400 µL of phosphate-buffered saline (PBS), sonicated to break apart any 11 
clumps that may have formed during the incubation period, and subsequently separated by 12 
centrifugation at 6,708×g for 10 minutes. After two additional wash steps conducted in 500 µL 13 
PBS, protein-coated microbeads were re-suspended in 3 mL of 1.5% BSA, which served to block 14 
non-specific binding, finally yielding a concentration of 400,000 particles/µL. 15 
The control group of microbeads was washed as described above. However, following 16 
the third wash step the microbeads were re-suspended in 2% BSA and incubated overnight with 17 
gentle vortexing. The suspension of control microbeads were washed twice in PBS and re-18 
suspended in 1.5% BSA immediately before an adhesion assay was performed.  19 
Preparation of human platelets 20 
Human venous blood was collected from healthy consenting volunteers into 4 mL 21 
Vacutainer tubes (K2EDTA, BD, Franklin Lakes, NJ) and used within 4 hours of donation.  22 
Platelet rich plasma was prepared by centrifugation of whole blood samples (400×g, 4 min). 23 
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Whole blood and platelet rich plasma were analyzed for platelet and red blood cell content using 1 
a hemocytometer (BD, Franklin Lakes, NJ). Platelet rich plasma was then diluted with PBS to 2 
the desired platelet concentration, and then used immediately in the adhesion experiments. 3 
Cell-free model to study GP Ibα-mediated platelet adhesion 4 
We developed a well-controlled system consisting of carboxylate-modified fluorescent 5 
microbeads to quantitatively describe GP Ibα-mediated platelet adhesion to stimulated 6 
endothelial cells. The microbead diameter (2.0 µm) was selected based on measured diameters of 7 
human and mouse platelets (0.5 to 3.0 µm [43, 44]). Each platelet has 15,000 to 25,000 copies of 8 
GP Ibα [45, 46]. Based on this estimation and using the literature value of 50 µm2 [47] for the 9 
surface area of a washed human platelet, the lower bound for the GP Ibα density  is about 300 10 
sites/µm2. Assuming spherical geometry, our microbeads were coated with GP Ibα at this value 11 
of the receptor density. It is anticipated that a higher density of GP Ibα will make the effects we 12 
observed more pronounced. The concentration of microbeads in the BSA solution (400,000 13 
particles /µL) was carefully controlled in adhesion assays to mimic platelet-endothelial 14 
interactions in vivo. The range of platelet concentrations in human blood is between 150,000 and 15 
450,000  platelets/µL [48].  16 
 17 
Static Adhesion Experiments 18 
Confluent groups of HUVEC in a 24-well tissue culture plate were left untreated 19 
(control) or incubated with TNF-α (50 ng/mL), histamine (10-6 mol/L), or their combination for 20 
one hour at 37ºC. In the combined activation group, histamine was introduced into the growth 21 
medium 30 minutes into the TNF-α activation period. The supernatant from each well was then 22 
removed and GP Ibα-coated microbeads were applied to HUVEC for five minutes. All wells 23 
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were then washed three times with PBS to remove any microbeads that had not firmly attached 1 
to the endothelium. After the wash procedure had ended, the wells were imaged under an 2 
inverted microscope (Nikon Eclipse TiS) using 40X objective. Four randomly selected images 3 
from each well were captured with a CCD camera (QImaging Retiga EXi), and saved in the 4 
TIFF format at a resolution of 1392×1040 pixels.  5 
Anti-body blocking experiments were also conducted to evaluate the influence of GP 6 
Ibα-vWF binding under the inflammatory conditions studied. The vWF blocking assay was 7 
identical to the static adhesion assay with the exception that the cells in the blocking antibody 8 
groups were incubated with 6.7 µL of V3P in 200 µL of 2% BSA in PBS for 30 minutes at 37ºC 9 
immediately following TNF-α and/or histamine incubation, while other groups received just 2% 10 
BSA in PBS. GP Ibα-coated microbeads were then applied and imaged as described above. 11 
Static adhesion of washed human platelets to histamine-activated endothelium was also 12 
analyzed to validate the cell-free platelet model. In this experiment, HUVEC were stimulated 13 
with 0, 10-4, or 10-6 mol/L of histamine for five minutes before applying GP Ibα-coated 14 
microbeads and/or platelets. The platelet and microbead adhesion to HUVEC was quantified 15 
through image analysis using a custom MATLAB script (Fig. 2). It should be noted that the 16 
systematic histamine concentration in blood can increase to 10-7 mol/L during allergic attack 17 
[49]. The local concentration of serum histamine several minutes to hours after allergen exposure 18 
may far exceed its measured systematic value. Spikes in the histamine concentration to much 19 
higher than 10-7 mol/L may occur locally in the tissue containing a large number of activated 20 
mast cells. To model this situation, we considered the histamine concentration of   10-6 mol/L in 21 
the majority of experiments. 10-4 mol/L histamine was used only for short-term (5 minutes) 22 
activation of HUVEC for the model validation purpose. It should be noted that histamine with 23 
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this concentration was used in numerous in vitro experiments [50-54]. 10-4 mol/L is a threshold 1 
concentration for the histamine effect on leukocyte rolling [29]. This level is shown to saturate 2 
the vWF response [16, 30]. 3 
 4 
Flow Chamber Experiments 5 
 GP Ibα-coated microbeads were perfused over confluent HUVEC monolayers cultured in 6 
a commercially available microfluidic flow chamber (Bioflux 200, Fluxion Biosciences, San 7 
Francisco, CA). Briefly, passage 3-5 HUVEC were seeded in gelatin-coated micro-channels of a 8 
48-well Bioflux plate at a density of 5x106 cells/mL. The width and height of these micro-9 
channels were 350 and 70 µm, respectively. Media changes were performed twice daily for 2-3 10 
days until confluence was reached. Confluent HUVEC monolayer in micro-channels were left 11 
untreated (control) or exposed to selected inflammatory mediators (50 ng/mL of TNF-α, 10-6 12 
mol/L of histamine, or their combination) for one hour. Following the activation period, 13 
HUVEC-lined micro-channels were washed by perfusion with the growth medium (M200). 14 
Fluorescent GP Ibα-coated microbeads were then perfused over each micro-channel for a period 15 
of 2 minutes under physiologic shear flow conditions (wall shear stress of 0.6 dyn/cm2, wall 16 
shear rate of ~70 s-1).  Fluorescent images of the flowing beads were visualized using a 10X 17 
objective in an inverted microscope (Nicon Eclipse TiS), and a total of 2400 images per micro-channel 18 
were captured by a digital CCD camera (Qimaging Retiga EXi) at 20 frames/s. The number of 19 
microbeads slowly rolling along the stimulated endothelium was quantified frame-by-frame 20 
using methods similar to the analysis of static adhesion (see below) and normalized to the 21 
control.  22 
 23 
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Quantification of Microbead and Platelet Adhesion 1 
Digital images were analyzed using a custom program written in MATLAB® 2 
(Mathworks, Natick, MA). Briefly, the original image (Fig. 1A) was imported into MATLAB® 3 
as an array of intensity values. The image contrast was increased and further adjusted by the 4 
Contrast Limited Adaptive Histogram Equalization (CLAHE) technique using the image 5 
processing toolbox of MATLAB (Fig. 1B). Following contrast standardization, the grayscale 6 
image was converted into a binary, black and white image. The edges of the objects (including 7 
beads, cells, and debris) in this image were then detected using an edge-detection algorithm with 8 
a Sobel filter (Fig. 1C). The image was then dilated, the holes within closed borders were filled 9 
in, and any objects contacting the border of the image were removed. The filled image with clear 10 
borders then underwent a two-stage erosion algorithm, which isolated partially connected and 11 
small objects within the image. The debris field resulting from the erosion step consisted of small 12 
amorphous objects representing cellular fragments (Fig. 1D), which were then removed from the 13 
image through a morphological opening algorithm (Fig. 1E). Any remaining small objects were 14 
finally removed using a filter targeting objects with an area less than 110 pixels, or 60% of the 15 
calculated average microbead area. The perimeter of the remaining objects in the resulting black 16 
and white image outlining only the microbeads of interest was determined. The original image 17 
was then overlaid with the enhanced green-colored borders of the microbeads (Fig. 1F).  18 
Morphologically opened images (Fig. 1D) depict adherent microbeads, i.e., the 19 
microbeads left after the wash procedure, as white ‘blobs’ completely surrounded by the black 20 
background.  Since closely associated microbeads may be counted as one object by this method,  21 
we first determined the average pixel-area of a microbead within the sequence of 36 to 48 22 
images. 12 microbeads were selected from the images and their area was averaged, yielding the 23 
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value of 205 pixels per microbead. The number of microbeads within each blob was then 1 
calculated by dividing the area of the blob by the pre-determined single microbead area. This 2 
number was summed over all blobs to determine the total number of adherent microbeads in the 3 
image. 4 
 5 
Figure 1: Digital image analysis technique used to quantify adhesion of microbeads and 6 
platelets to HUVEC.  (A) Original image.  (B) Image following contrast enhancement to 7 
facilitate detection of the edges of microbeads or platelets (point to black spots). (C) Dark 8 
objects were outlined based on their grayscale intensity relative to the background. (D) These 9 
borders were used to generate a binary image with filled areas between closed borders.  (E) 10 
Cellular debris and other unwanted objects in the closed-border image were removed through 11 
morphological opening algorithm, followed by a dilation filter to remove small objects, 12 
producing a binary representation of adherent microbeads/platelets. (F) This binary image was 13 
used to generate borders of microbeads/platelets which were then overlaid onto the original 14 
image for visualization. 15 
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Statistical Analysis 1 
In static adhesion experiments, the data from four images per well were averaged together for 2 
three wells examined per experimental group. For flow experiments, the number of slow rolling 3 
microbeads was calculated on a frame by frame basis, which was then averaged across the entire 4 
image sequence. Reported is the mean flux of rolling microbeads averaged across each 5 
individual microchannel, generating five individual data points from 12000 images that were 6 
analyzed. All independent experiments were done in triplicate. Results are presented as the mean 7 
± standard error of the mean (SEM). Statistical analysis was evaluated using a two-tailed, 8 
unpaired Student’s t-test. P-values less than 0.05 were considered statistically significant. 9 
Results 10 
Cell-Free Platelet Model Validation 11 
GP Ibα-coatedmicrobeads were evaluated against BSA-coated microbeads to assess non-12 
specific interactions to the tissue culture plate, gelatin coating, resting endothelium, and 13 
histamine-stimulated endothelium. Both BSA and GP Ibα-coated microbeads were applied to 14 
gelatin-coated tissue culture plates in order to demonstrate the latex microbead interactions are 15 
HUVEC-dependent (Fig. 2A). The specificity of GP Ibα-coated microbeads for the HUVEC 16 
monolayer was then evaluated on both resting HUVEC and HUVEC stimulated with 10-4 M 17 
histamine in M200 for 5 minutes (Fig. 2B).  18 
Figure 3A shows that GP Ibα-coated microbeads (small bright circles) were minimally 19 
adherent to the resting HUVEC monolayer. Following stimulation with 10-4 mol/L of histamine, 20 
secreting ULVWF on HUVEC promoted increased microbead adhesion, and endothelial cells 21 
retracted pseudopods and became round in shape with more gaps between cells (Fig. 3B). Only a 22 
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few human platelets (white amorphous dots) were seen attached to the resting endothelium (Fig. 1 
3C). As in studies using microbeads, stimulation with 10-4 mol/L of histamine has been observed 2 
to induce endothelial secretion of ULVWF which occurred primarily in a basolateral direction 3 
and created gaps in the previously confluent monolayer (Fig. 3D). Thus, both platelets and GP 4 
Ibα-coated microbeads adhered primarily around the periphery of stimulated HUVEC, which is 5 
consistent with the localized presence of ULVWF in this region.  6 
 7 
 8 
Figure 2: Specificity of GP Ibα-coated microbead adhesion to HUVEC. (A) Neither GP Ibα- nor 9 
BSA-coated microbeads adhered in any significant manner to the 0.1% gelatin-in-PBS (gel) 10 
substrate, however, GP Ibα-mediated adhesion increased significantly from 0.0355 ± 0.0175 11 
beads per frame (BPF) on gelatin to 6.49 ± 1.12 BPF on HUVEC. (B) GP Ibα-coated 12 
microbeads adhere significantly stronger to HUVEC monolayer than do BSA-coated 13 
microbeads: 5.29 ± 0.966  GP Ibα-coated microbeads were bound per frame on resting HUVEC, 14 
compared to 1.67 ± 0.631 BSA-coated microbeads. Histamine had no significant effect on BSA 15 
adhesion (1.67 ± 0.631 vs 1.96 ± 0.522). However, GP Ibα adherence was significantly greater 16 
to histamine-stimulated HUVEC (15.0 ± 3.03 BPF) compared to resting HUVEC (5.29 ± 0.966  17 
BPF). Shown are Mean ± SEM of six independent data points. * p < 0.05, ** p < 0.01. 18 
 19 
 20 
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 1 
Figure 3: Phase-constrast images showing adhesion of microbeads (A,B) and platelets (C,D) to 2 
resting and stimulated HUVEC. (A) GP Ibα-coated microbeads (small bright circles) were 3 
minimally adherent to a resting HUVEC monolayer. (B) Following stimulation with 10-4 mol/L 4 
of histamine, endothelial cells retract pseudopods and become round in shape, forming gaps in 5 
the previously confluent monolayer. Adherent GP Ibα-coated microbeads are found around the 6 
periphery of histamine-activated endothelial cells due to the localized presence of ULVWF 7 
strings in this region. (C) Human platelets (tiny white specs against grey background and cells) 8 
adhere minimally to  a resting HUVEC monolayer. (D) HUVEC stimulation with 10-4 mol/L of 9 
histamine significantly increases platelet adhesion to HUVEC borders. 10 
 11 
Figure 4 demonstrates that both platelets and GP Ibα-coated microbeads adhere to 12 
histamine-stimulated endothelium in a dose-dependent fashion. As seen in Fig. 4A, stimulation 13 
with 10-4 mol/L of histamine significantly (p < 0.0001) increased the number of adherent 14 
microbeads to 4.49 ± 0.600 times that of the control. Similarly, the number of adherent platelets 15 
significantly (p < 0.05) increased to 3.16 ± 0.745 of the control value following stimulation with 16 
the same dose of histamine. Figure 4B depicts the data shown in Fig. 4A with normalized 17 
adherence of GP Ibα-coated microbeads plotted against the normalized adhesion of washed 18 
human platelets. A linear regression gave us the equation of the best-fit line for our data (Fig. 19 
15 
 
 
4B), yielding an r2 value of 0.999. This indicates that there exists a strong correlation between 1 
GP Ibα-coated microbead and platelet adhesion to activated endothelium.  2 
 3 
 4 
Figure 4: Correlation in microbead and platelet adhesion to stimulated HUVEC under static 5 
conditions (A) Both human platelets (PLT) and GPIbα-coated microbeads adhere to histamine-6 
stimulated endothelium in a concentration dependent manner. Here, 10-4 M and 10-6 M indicate 7 
HUVEC incubation with 10-4 mol/L and 10-6 mol/L of histamine, respectively. (B) The 8 
correlation curve constructed from the GPIbα and PLT data in (A). Dotted lines show the 95% 9 
confidence interval. The correlation coefficient r2= 0.999. Mean ± SEM of nine independent data 10 
points, normalized to GPIbα-coated microbead control with basis 1 * p < 0.05, *** p < 0.0001. 11 
 12 
Combined effect of TNF-α and histamine  13 
As in the case of HUVEC exposed to histamine alone (Fig. 4A), the one hour incubation 14 
of HUVEC with 50 ng/mL of TNF-α significantly increased the number of adherent GP Ibα-15 
coated microbeads (2.47 ± 0.392 of the control value, p < 0.05) (Fig. 5A). However, when TNF-16 
α was co-incubated with 10-6 mol/L of histamine, a significant decrease (p < 0.05, 52.7%) in 17 
microbead adhesion was observed, when compared to the TNF-α alone activation. As seen in 18 
Fig. 5A, the number of microbeads adherent to TNF-α + histamine-activated endothelium was 19 
just 1.17 ± 0.187 of the control value. Figure 5B shows that the observed effects of TNF-α and 20 
histamine can be blocked by HUVEC incubation with a monoclonal antibody VP3 directed 21 
against the A1 domain of vWF. Specifically, adding this antibody to resting, TNF-α-activated, 22 
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and TNF-α + histamine-activated endothelium reduced the number of adherent microbeads to 1 
0.714 ± 0.0714, 0.929 ± 0.228, and 0.696 ± 0.142 of the control value, respectively. Thus, both 2 
TNF-α effect and the decrease in the number of adherent microbeads with histamine stimulation 3 
of TNF-α-activated endothelium are associated with changes in the concentration of ULVWF 4 
strings anchored to endothelium.  5 
The GP Ibα-coated microbead adhesion to HUVEC exposed to single and multiple 6 
inflammatory mediators was quantified under flowing conditions (Fig. 6). HUVEC monolayers 7 
stimulated with 10-6 mol/L of histamine demonstrated a slight, but not significant, increase in the 8 
number of slow rolling microbeads (measured as beads per frame (BPF) normalized against the 9 
control) than did the unstimulated HUVEC monolayer (1.25 ± 0.181 vs. 1.00 ± 0.0944, i.e., 25% 10 
increase). Stimulation with 50 ng/mL of TNF-α produced a significantly (p < 0.05) greater effect 11 
on GP Ibα-mediated adhesion, resulting in a 33% increase in the number of slow rolling 12 
microbeads compared to the control (1.33 ± 0.0916). As in static adhesion experiments, the 13 
number of microbeads interacting with TNF-α-activated HUVEC under flow was significantly (p 14 
< 0.05) lower when HUVEC was additionally stimulated with histamine (1.01 ± 0.041 vs. 1.33 ± 15 
0.0916). It is worth mentioning that GP Ibα-coated microbeads were observed to adhere to the 16 
periphery of the endothelial cells under flow conditions, which is slightly different from the 17 
behavior of platelets that adhere like “beads on a string” [19]. This discrepancy may be attributed 18 
to the lack of secondary adhesion receptors such as GPIIb/IIIa (αIIbβ3), which would form 19 
stronger bonds with vWF than GP Ibα. 20 
 21 
 22 
 23 
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 1 
 2 
Figure 5: Effect of TNF-α and histamine on adhesion of GP Ibα-coated microbeads (GP1b-α) to 3 
HUVEC under static conditions. (A) HUVEC exposure to TNF-α at 50 ng/mL for 60 minutes 4 
significantly increases microbead adhesion to HUVEC. When 10-6 mol/L of histamine (HIST) 5 
was added alongside TNF-α, a significant decrease in microbead adhesion was observed. (B) 6 
For each inflammatory regime tested in (A), the same experiment was performed in the presence 7 
of a monoclonal antibody VP3 directed against the vWF A1 domain. A 30 minute incubation 8 
period with VP3 resulted in reduced microbead adhesion to near control values. Mean ± SEM of 9 
nine independent data points, normalized to control with basis 1. * p < 0.05. 10 
 11 
 12 
Figure 6: Effect of TNF-α and histamine (Hist) on 13 
adhesion of GP Ibα-coated microbeads  to HUVEC 14 
under flow conditions. The number of slow rolling 15 
microbeads increases with HUVEC exposure to 10-6 16 
mol/L of histamine or 50 ng/mL of TNF-α. The 17 
combined exposure of HUVEC to TNF-α and 18 
histamine, however, results in a significant decrease in 19 
rolling adhesion of microbeads,  compared to TNF-α 20 
alone stimulation. Mean ± SEM of six independent data 21 
points, normalized to control with basis 1. * p < 0.05.  22 
 23 
 24 
 25 
Discussion 26 
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The results presented in this report suggest that histamine may play a dual role in platelet 1 
adhesion to vascular endothelium. When applied to resting endothelial cells, histamine increases 2 
the number of ULVWF strings on the endothelial surface and thus induces platelet accumulation 3 
on endothelial cells, in line with published data [16]. However, if histamine is released near 4 
endothelium activated by inflammatory mediators such as TNF-α, it may have an inhibitory role 5 
in GP Ibα-mediated platelet-endothelial cell interactions. This is most likely caused by the 6 
histamine-induced detachment of endothelium-anchored ULVWF strings secreted after TNF-α 7 
exposure. This detachment may occur, for example, due to histamine-induced F-actin 8 
redistribution in endothelial cells with disappearance of dense peripheral bands of F-actin and 9 
stress fibers [55, 56]. The weakening and rearrangement of the actin cytoskeleton induced by 10 
histamine may reduce the strength of ULVWF binding to the endothelial cell surface [57].  The 11 
dual, paradoxical effect of histamine on platelet-endothelium adhesion may be one of the reasons 12 
behind conflicting reports on the role of mast cells in thrombosis. Mast cell-deficient mice were 13 
found to be more susceptible to lethal thromboembolism than wild-type mice, and evidence 14 
shows that mast cells accumulate at sites of venous thrombosis, where they serve as repair cells 15 
[58, 59]. On the other hand, mast cells activated by diesel exhaust particles were found to initiate 16 
inflammation and thrombosis in the lungs of hamsters [60]. Thus, histamine released from mast 17 
cells may cause or inhibit thrombosis, depending on whether it acts on resting endothelial cells or 18 
on cells pre-activated by other inflammatory stimuli.   19 
A large number of mast cells are colocalized with macrophages in atherosclerotic plaques 20 
[35], where their activation leads to a significant increase in local histamine concentration [36, 21 
37, 61]. Our data underlines the need for understanding whether mast cells are already present at 22 
sites where atherosclerosis would be developed or they migrate to early atherosclerotic lesions in 23 
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response to stimuli released by activated cells in these regions. In the former case, platelet 1 
adhesion to histamine-activated arterial endothelium could initiate atherosclerosis. Indeed, 2 
adherent platelets can capture flowing monocytes via platelet P-selectin binding to monocyte 3 
PSGL-1 [41, 62]. This leads to the accumulation of monocytes in the intimal layer of an artery, 4 
where monocytes differentiate into macrophages and then foam cells. If the latter case is true, 5 
histamine release from mast cells will have an anti-thrombotic effect on dysfunctional 6 
endothelium at the plaque. However, activated mast cells will still cause monocyte adhesion and 7 
transendothelial migration. Indeed, our recent investigation [63] shows that the number of slow 8 
rolling and firmly adherent monocytes is higher on endothelium activated sequentially by TNF-α 9 
and histamine than that on endothelium activated by TNF-α alone, with no slow rolling or firm 10 
adhesion events observed when endothelial cells are exposed to histamine alone. This 11 
synergestic effect indicates that histamine release from mast cell may lead to direct capture of 12 
monocytes by endothelium (i.e., without involvement of platelets) provided endothelium is pre-13 
activated by TNF-α.  14 
The methods used in this work are well suited to study functional characteristics of 15 
receptor-ligand interactions involved in thrombosis. Fluorescent latex microbeads can be 16 
covalently coated with platelet, leukocyte, or any other recombinant protein at physiologically 17 
relevant concentrations, forming a model ideal for studying adhesion, translocation, and 18 
aggregation under well controlled conditions free from the involvement of other proteins, 19 
cytokines, and cellular elements present in previous studies using viable platelets or CHO cells 20 
[16, 62]. Furthermore, the difficulty in working with human platelets has impeded their use in 21 
quantitative studies. Platelets become activated extremely easily, for instance, centrifuging 22 
platelets in PBS yields a platelet pellet which cannot be broken apart and re-suspended. For these 23 
20 
 
 
reasons, we propose the use of GP Ibα-coated microbeads as a model to evaluate platelet 1 
adhesion to the vascular endothelium, the first step in thrombosis and related pathologies. 2 
In summary, we developed a cell-free model of a human platelet by covalently coating 3 
latex microbeads with human recombinant GP Ibα.  Using this model, we were able to quantify 4 
GP Ibα-mediated platelet adhesion to histamine- and/or TNF-α-activated endothelium under 5 
static and flow conditions. The results of this work demonstrate that histamine may have both 6 
stimulatory and inhibitory effects on platelet-endothelial adhesion: resting endothelium exposed 7 
to histamine is more adhesive to platelets, while histamine exposure of TNF-α-activated 8 
endothelium leads to reduced adhesion of platelets. Future studies will specifically examine the 9 
role of mast cell activation in platelet-endothelial cell interactions.   10 
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